Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
The Pharma Data
SEPTEMBER 16, 2020
New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Blueprint Medicines will present new data from the registrational phase I/II ARROW trial, investigating Gavreto TM (pralsetinib) for the treatment of people with RET-mutant medullary thyroid cancer.
Let's personalize your content